Oncogenic Runx1–Myc axis in p53-deficient thymic lymphoma-Reference-Cited by-同舟云学术

Oncogenic Runx1–Myc axis in p53-deficient thymic lymphoma

Published:2022-04 Issue: Volume:819 Page:146234
ISSN:0378-1119
Container-title:Gene
language:en
Short-container-title:Gene

Author:

Date Yuki,Taniuchi Ichiro,Ito Kosei

Funder

Nagasaki University

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Genetics,General Medicine

Reference55 articles.

1. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation;de Alboran;Immunity,2001

2. GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia;Belver;Cancer Discovery,2019

3. Runx1 promotes B-cell survival and lymphoma development;Blyth;Blood Cells Mol. Dis.,2009

4. Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging;Blyth;Oncogene,2001

5. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss;Blyth;Oncogene,1995

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma;Leukemia & Lymphoma;2024-09

2. Myc upregulates Ggct, γ‐glutamylcyclotransferase to promote development of p53‐deficient osteosarcoma;Cancer Science;2024-06-26

3. Myc upregulates Ggct, γ-glutamylcyclotransferase to promote development ofp53-deficient osteosarcoma;2024-03-19

4. Increased RUNX1 mutations in breast cancer disease progression;Pathology - Research and Practice;2024-02

5. Targeting sphingosine kinase 1 in p53KO thymic lymphoma;The FASEB Journal;2023-10-06